Investigation of a Lomentospora prolificans case cluster with whole genome sequencing by Boan, P. et al.
Contents lists available at ScienceDirect
Medical Mycology Case Reports
journal homepage: www.elsevier.com/locate/mmcr
Investigation of a Lomentospora prolificans case cluster with whole genome
sequencing
Peter Boana,b,∗, Stanley Pangc, Dianne J. Gardamb, Helen Darraghb, Matthew Wrighta,b,
Geoffrey W. Coombsb,c
a Fiona Stanley Hospital, 11 Robin Warren Ave, Murdoch, Perth, 6150, Australia
b PathWest Laboratory Medicine WA, 11 Robin Warren Ave, Murdoch, Perth, 6150, Australia
cMurdoch University, 90 South St, Murdoch, Perth, 6150, Australia
A R T I C L E I N F O
Keywords:
Lomentospora prolificans
Scedosporium prolificans
Fungal outbreak
Whole genome sequencing
Antifungal resistance
A B S T R A C T
Lomentospora prolificans has caused outbreaks in immunocompromised patients. We performed whole genome
sequencing (WGS) on 4 L. prolificans isolates from infections occurring during an 8-month period in the hae-
matology unit at Hospital 1., and 2 isolates from unrelated infections at Hospital 2., showing a high number of
mutational differences (> 10,000 single nucleotide polymorphisms) between L. prolificans isolates from Hospital
1. Novel typing of isolates by WGS did not demonstrate a single causative strain.
1. Introduction
Lomentospora prolificans is an environmental mold which is found
particularly in Australia, Spain, Portugal, California and the southern
United States [1]. It characteristically causes clinical infection in im-
munocompromised hosts and is notable for resistance to antifungals.
Invasive disease occurs mainly in patients with haematological disease,
stem cell transplantation and lung transplantation, with fewer cases in
AIDS patients [2,3]. Overall mortality due to infection is high at 46.7%,
with almost universal mortality with disseminated disease of 87.5%
[2]. A cluster of clinical cases in our haematology unit prompted an
examination for an environmental source and testing of the isolates to
determine if a single strain caused the infections.
2. Clinical case presentation
We included four cases in the haematology unit at Hospital 1 which
were all the probable or proven invasive L. prolificans infections in the
hospital during an eight-month period according to established defini-
tions [4]. Table 1. summarises the case demographics, underlying ill-
ness, clinical manifestations, antifungal therapy, and outcomes.
Case 1. (C1H1) was a 53 year old male with background of liver
cirrhosis, type 2 diabetes mellitus and diffuse large B-cell lymphoma.
He had a matched unrelated stem cell transplant 5th February 2015,
complicated by acute graft-versus-host-disease treated with
prednisolone and sirolimus, acute kidney injury requiring
haemodialysis, and intensive care unit admission. He was on
fluconazole prophylaxis. On the 19th May 2015 (Day 0) necrotic soft
tissue was noticed at his heel. Swab D0, swab D+2 and tissue D+6
grew L. prolificans (fungal microscopy negative by Calcofluor White
stain). MRI showed localized osteomyelitis of the calcaneum and
overlying soft tissue inflammation. There were no abnormalities on
CT chest and sinuses. On D+3 he commenced oral voriconazole with
loading doses 400 mg b.d. on day one, followed by 200 mg b.d. (weight
88 kg), and oral terbinafine 250 mg once daily (creatinine clearance
54 ml/min). Serum voriconazole level was not obtained. D+15 he
complained of new abdominal pain and was relatively hypotensive. The
following day (D+16) he was found unresponsive, deceased.
Case 2. (C2H1) was a 71 year old female with chronic obstructive
pulmonary disease who was diagnosed with chronic lymphocytic
leukemia. This was treated with fludarabine, cyclophosphamide and
rituximab in April 2015 without antifungal prophylaxis. She presented
26th May 2015 with fatigue, sweats, cough, and chest pain. CT chest
showed nodules with surrounding halo sign suggestive of pulmonary
mold infection. Expectorated sputum 27th May 2015 grew Klebsiella
pneumoniae and a prior sputum taken 17th April 2015 had grown
Aspergillus niger and Aspergillus terreus. She was treated with
antibacterials and oral voriconazole 300 mg b.d., trough levels
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0.6–1.3 mg/L, and it was ceased 2nd July. She had a rise in
inflammatory markers and development of soft tissue nodules 7th
July 2015 (D0). Disseminated infection was strongly suspected as
hyphal elements were seen by Calcofluor White microscopy and L.
prolificans was grown from urine and sputum, and hyphae and
granulomatous inflammation were seen from biopsy of a soft tissue
nodule (no growth, direct fungal PCR negative). CT chest and abdomen
D+2 showed improved nodular lung lesions and no abnormalities in
the kidneys. Blood culture was negative. Pending culture results,
empirical liposomal amphotericin 400 mg once daily (patient weight
~80 kg) was commenced D0 to D+5, adding voriconazole
(intravenous, 500 mg b.d. day one, then 300 mg b.d. ongoing) at D
+2 with provisional Scedosporium spp from culture of urine and
sputum. With identification of L. prolificans at D+7, we added oral
terbinafine 250 mg once daily (creatinine clearance 20 ml/min) and IV
anidulafungin (200 mg daily loading dose day one, then 100 mg daily
ongoing) to ongoing voriconazole. Voriconazole trough level was
4.1 mg/L on D+9. On D+10 she developed sudden onset
breathlessness, hypoxia with a bland chest X-ray, followed by
reduced conscious state, and died D+12.
Case 3. (C3H1) was a 63 year old male admitted 5th July 2015 with a
new diagnosis of acute myeloid leukemia, treated with idarubicin and
cytarabine with oral posaconazole MR tablet 300 mg antifungal
prophylaxis, trough level on the 15th July of 1.7 mg/L. Febrile
neutropenia with abdominal pain developed 14th July, and CT
abdomen showed right colon wall oedema and stranding consistent
with typhlitis. Escherichia coli was grown from blood 14th July, and L.
prolificans was grown from blood 19th July (D0), and also from blood
cultures on D+2, D+3, and D+4. On D+2 he started IV voriconazole
400 mg b.d. (weight 72 kg, so 5.6 mg/kg/dose), oral terbinafine
500 mg b.d. (creatinine clearance 38 ml/min), and IV anidulafungin
(200 mg day one, followed by 100 mg daily ongoing). On D+2 he
complained of a painful eye however no vitreous or retinal pathology
was evident by ophthalmologist examination and CT eye was
unremarkable. On D+3 he developed hypotension, acute kidney
injury, bilateral hilar infiltrates on chest X-ray, and coagulopathy. He
died D+5.
Case 4. (C4H1) was a 25 year old female with acute myeloid leukemia
who had a matched unrelated stem cell transplant 30th December
2015. L. prolificans grew from blood culture taken 7th January 2016
(D0), when she had febrile neutropenia, CT abdomen evidence of
typhlitis, and sinus opacification without bony erosion on CT sinuses.
CT chest was unremarkable. She was commenced D+4 on IV
voriconazole (loading dose 400 mg b.d. day one, followed by
250 mg b.d., weight 64 kg), oral terbinafine 500 mg b.d. ongoing
(creatinine clearance 100 ml/min), and IV anidulafungin (200 mg day
one, 100 mg daily ongoing).Voriconazole dose was increased to
400 mg b.d. D+33. The first trough voriconazole level at D+13 was
therapeutic at 3.2 mg/L, from D+32 to D+52 levels were
subtherapeutic 0.2–0.4 mg/L (the majority of voriconazole was given
orally in this period). Right sternoclavicular joint pain developed with
inflammatory changes on MRI D+40 and Fluorodeoxyglucose (FDG)
uptake on Positron emission tomography (PET) scan D+42. This was
surgically debrided D+50 and tissue samples grew L. prolificans after
10 days incubation. New areas of kidney hypoattenuation were seen by
CT abdomen D+57 (not present on PET scan), and urine taken D+61
grew L.prolificans. Miltefosine was added D+73 at 150 mg once daily,
reduced due to nausea to 120 mg once daily D+98, which was
continued. Voriconazole doses were increased stepwise at D+71
(250 mg b.d), D+73 (300 mg b.d.), D+93 (350 mg b.d.), D+99
(450 mg b.d.), and trough voriconazole levels in this period D+53 to D
+126 were slightly higher than before at 0.5–1.6 mg/L. With new back
pain, PET scan was repeated D+126 which showed new FDG uptake at
the S1 vertebra and the right 4th costosternal junction. Biopsy of the
4th costosternal junction grew L. prolificans after 6 days incubation.
From D+127 to D+147 trough voriconazole levels were 3.6–10 mg/L.
She developed acute abdominal pain with acidosis D+146 thought to
be secondary to gut graft-versus-host-disease, was palliated and died D
+149. Of note, the majority of the time voriconazole was given
intravenously, and she only had therapeutic levels on doses of
350 mg b.d. or higher suggesting she may have been a rapid or
ultrarapid metabolizer of voriconazole, however we never tested
cytochrome p450 2C19 alleles.
Case 5. (C5H2) was a 69 year old female without past medical history
who presented on 7th December 2016 with flexor tendon tenosynovitis
one week after a thorn injury. Tissue samples grew L. prolificans and she
was cured with several months of voriconazole with terbinafine. Trough
voriconazole levels were 0.6–1.1 mg/L. Doses were not recorded.
Case 6. (C6H2) was a 45 year old indigenous male from a remote
region of Western Australia. He had acute myeloid leukemia treated
with idarubicin and cytarabine from the 4th May 2015. He presented on
the 15th June 2015 with back pain, MRI demonstrated changes
consistent with osteomyelitis and discitis at L1 and L2 vertebrae.
Bone biopsy 20th June (D0) saw hyphal elements on Calcofluor
White microscopy and grew L. prolificans. He was treated with
voriconazole and terbinafine (doses not recorded). CT chest D+20
Table 1
Clinical characteristics of the cases with Lomentospora prolificans infection.
Case number Hospital GenBank accession no. Date of isolate Site of infection Age (yrs) Sex Disease Antifungal treatment Survival from positive isolate (days)
1 (C1H1) 1 SAMN10849956 19/05/15 Soft tissue 53 M AlloHCTa
Cirrhosis
Voriconazole
Terbinafine
16
2 (C2H1) 1 SAMN10849957 07/07/15 Disseminated 71 F CLLb Voriconazole
Terbinafine
Anidulafungin
12
3 (C3H1) 1 SAMN10849958 19/07/15 Disseminated 63 M AMLc Voriconazole
Terbinafine
Anidulafungin
5
4 (C4H1) 1 SAMN10849959 07/01/16 Disseminated 25 F AlloHCTa Voriconazole
Terbinafine
Anidulafungin
Miltefosine
149
5 (C5H2) 2 SAMN10849960 08/12/16 Tendon sheath 70 F Nil Voriconazole
Terbinafine
Alive
6 (C6H2) 2 SAMN10849961 20/06/15 Vertebrae 45 M AMLc Voriconazole
Terbinafine
56
a Allogeneic haematopoietic stem cell transplant.
b Chronic lymphocytic leukemia.
c Acute myeloid leukemia.
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showed a few nodules less than 10 mm diameter. Trough voriconazole
level D+22 was 0.2 mg/L, D+28 was 4.5 mg/L, D+40 was 0.4 mg/L,
D+45 was 2.2 mg/L, and D+52 was 1.2 mg/L. CT chest repeated D
+45 showed increasing infiltrates consistent with pulmonary mold
infection. He deteriorated acutely with respiratory failure and was
found unresponsive, deceased D+56.
In Hospital 1., some cases were admitted to the haematology ward
at the same time (Case 1. and Case 2.; and Case 2. and Case 3.), though
none of the four cases of Hospital 1. were admitted to a common room
on the ward at any time. The high-efficiency particulate air (HEPA)
filters in the air conditioning system and positive pressure airflow
systems in the rooms in which the patients were admitted had passed
routine checks during the period. At the time of these cases, there were
minor earthworks at a traffic light adjacent to the hospital and also
water leakage from plumbing at a distant part of the hospital. One cubic
metre of air for fungal culture was sampled in affected patient rooms,
other areas of the haematology ward, the cancer outpatient centre, the
main hospital concourse, car park and open grounds. Swabs for fungal
culture were taken from patient sinks and various other surfaces of
patient rooms in the haematology ward. However there was no growth
of L. prolificans from any of the environmental samples.
3. Identification and minimum inhibitory concentration testing
L. prolificans was identified by characteristic macroscopic and mi-
croscopic features in addition to in-house Sanger sequencing of the
internal transcribed spacer region 1 and 2 of the ribosomal DNA gene as
previously described [5]. Antifungal susceptibility testing was per-
formed by microbroth dilution with the Sensititre® YeastOne YO10
system (TREK Diagnostic Systems, West Sussex, UK). The study was
approved with a waiver of informed patient consent by the Fiona
Stanley Hospital Human Research and Ethics Committee, RGS number
191.
Minimum inhibitory concentrations (MICs) of the isolates from the
six clinical cases are presented in Table 2., showing very high MICs for
the triazoles, echinocandins and amphotericin B.
4. Whole genome sequencing
Isolates from Hospital 1. were compared to two unrelated isolates
from Hospital 2. Whole genome sequencing (WGS) using a Nextseq
platform was performed on the four isolates from the case cluster, two
unrelated isolates, and an ATCC isolate. A whole genome sequence of L.
prolificans strain (NCBI accession number NLAX00000000) was used as
the reference sequence [6]. The Illumina paired-end sequence data
were analysed to identify single nucleotide polymorphisms (SNPs) in
the core genome by comparison with the reference sequence with
Snippy version 4.0 (http://www.vicbioinformatics.com/software.
snippy.shtml). A maximum likelihood tree was constructed using
MEGA v7.0 with 1000 bootstraps [7].
By phylogenetic analysis there appeared to be L. prolificans isolates
circulating in both hospitals which diverged from a common ancestor
linking to the ATCC64913 strain (see Fig. 1.). Other than the close
genomic similarity shared between isolates from Case 5 and Case 3 (39
SNPs) for which there was no clinical connection, the other isolates
contain a high number of mutational differences (> 10,000 SNPs) be-
tween them. The results suggest no genetic relationship between the 4
clinically clustered cases in Hospital 1.
We decided not to change routine anti-mold prophylaxis of posa-
conazole to patients with acute myeloid leukemia and graft-versus-host-
disease because of the resistance of L. prolificans to antifungal agents
including high MICs for voriconazole and terbinafine, and we did not
extend anti-mold prophylaxis to patients who would not normally re-
quire it. Without any change in practice, no further cases occurred.
5. Discussion
The occurrence of four cases in an eight-month period of invasive L.
prolificans infection in our haematology unit at Hospital 1. was very
concerning due to the rarity of this pathogen, its resistance to antifungal
therapy and the high attributable mortality. WGS of the isolates sug-
gested it was not the same strain causing infection. This does not rule
out the possibility of a single common source involving multiple strains
of L. prolificans, however a source was not identified by environmental
sampling.
Other clusters or outbreaks with L. prolificans have been described.
Guerrero et al. described six haematology patients with invasive in-
fection with L. prolificans in a 14-month period. The organism was
identified from air samples from two rooms and PCR fingerprinting
suggested the two environmental samples and four clinical samples
were identical. In response, HEPA filters and positive pressure airflow
systems were installed into the rooms of the haematology ward, which
aborted the outbreak [8]. Alvarez et al. reported four fatal cases in
haematology patients over a one month period. At the time, the hae-
matology ward was being refurbished and haematology patients were
admitted to a standard ward with construction work occurring on the
same floor. No additional cases were identified after haematology pa-
tients were moved to an alternative floor [9].
During nosocomial fungal outbreaks more generally, construction
and disturbances to airflow systems are the commonest precipitants,
and haematology or bone marrow transplant units are the most fre-
quently affected patient groups. Suggested measures for prevention
include communication between hospital engineering and infection
prevention teams, risk assessments of construction work, measures to
control the airborne dissemination of fungal spores such as barriers and
portable HEPA filters, and surveillance for health-care associated mold
infection [10].
L. prolificans is notorious for being resistant to azoles, echinocandins
and polyenes. Current guidelines suggest treatment of voriconazole
with terbinafine [11], however these antifungals are barely active [3]
and consequently outcomes in immunocompromised patients are very
poor [1], as was illustrated in our study. Miltefosine has in vitro activity
with MICs of approximately 4 mg/L and in vitro led to a major re-
duction in amphotericin B and voriconazole MICs when combined with
these antifungals [12]. Steady-state serum concentrations of 15–40 mg/
L have been reported at the end of miltefosine treatment for visceral
leishmaniasis, although it should be noted that the drug is highly pro-
tein bound (96%) in serum [13]. Miltefosine has been used with some
success in combination with voriconazole and terbinafine [14], and
Table 2
Antifungal minimum inhibitory concentrations of the Lomentospora prolificans isolates.
Case number Itraconazole Posaconazole Voriconazole Anidulafungin Caspofugin Micafungin Amphotericin
1 (C1H1) >16 8 2 2 1 1 8
2 (C2H1) >16 >8 >8 2 1 2 >8
3 (C3H1) 16 >8 >8 2 8 4 >8
4 (C4H1) >16 >8 8 2 4 2 4
5 (C5H2) >16 >8 4 2 2 2 >8
6 (C6H2) >16 >8 8 2 1 2 >8
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may have prolonged survival in Case 4. in our study where it was uti-
lized in combination with voriconazole, terbinafine and anidulafungin.
Active antifungals are urgently required for L. prolificans. In vitro ac-
tivity is evident for some novel antifungals such as ibrexafungerp,
fosmanogepix, AR-12 and olorofim [15,16]. Results are eagerly awaited
for olorofim as the agent most progressed along clinical development,
with a global open-label phase 2b clinical study (FORMULA-OLS,
NCT03583164) recruiting patients with difficult fungal infection in-
cluding lomentosporiosis [17].
In summary, we have reported four cases of L. prolificans infection in
haematology patients at a single institution in an eight-month period
for which no common link was found. The infections were all fatal,
generally within weeks of fungal diagnosis. WGS as a novel molecular
epidemiological tool for this organism suggested the infections were not
caused by a single strain. We could not find an environmental source by
sampling, and without a change in practice, fortunately cases ceased to
occur.
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